Finally, among a panel of anti-TMIGD2 mAbs generated by us, clones 17C7 and 20F2 demonstrated therapeutically effects in vitro and in vivo by using primary human AML samples. This evidence concerns the gene TMIGD2 and acute myeloid leukemia.